[68Ga]Ga-DOTATATE PET/CT在鼻咽癌中的生长抑素受体显像
这项前瞻性研究纳入36例非角化型鼻咽癌患者,评估[68Ga]Ga-DOTATATE PET/CT的可行性及其无创检测SSTR2表达的能力。结果显示原发灶和区域淋巴结转移灶的[68Ga]Ga-DOTATATE摄取高于[18F]FDG,骨和内脏转移灶摄取相当;大多数鼻咽癌病灶高表达SSTR2,且与[68Ga]Ga-DOTATATE摄取强相关。
要点
- 原发灶[68Ga]Ga-DOTATATE的SUVmax为12.03,高于[18F]FDG的10.07(P=0.048)。
- 区域淋巴结转移灶[68Ga]Ga-DOTATATE中位SUVmax为9.11,高于[18F]FDG的6.12(P<0.001)。
- 85.7%的鼻咽癌病灶高表达SSTR2,SSTR2阴性病灶SUVmax显著低于阳性病灶(4.95 vs 12.61,P=0.013)。
核心结论
- [68Ga]Ga-DOTATATE PET/CT在检测鼻咽癌原发灶和转移灶方面是有前景的显像方法,图像对比度好,诊断效能与[18F]FDG PET/CT相当。
- 大多数鼻咽癌病灶高表达SSTR2,且SSTR2表达与[68Ga]Ga-DOTATATE摄取显著相关。
研究设计与样本
- 前瞻性研究,纳入2021年2月至5月间接受[68Ga]Ga-DOTATATE PET/CT的鼻咽癌患者,共36例参与者(25例初诊分期,11例复发检测),其中33例还接受了[18F]FDG PET/CT。
主要发现
- [68Ga]Ga-DOTATATE PET/CT在原发和转移性鼻咽癌病灶中显示强烈示踪剂摄取。
- 原发鼻咽癌病灶的[68Ga]Ga-DOTATATE摄取高于[18F]FDG(SUVmax:12.03 vs. 10.07,P=0.048;肿瘤/脑比值:36.16 vs. 0.86,P<0.001)。
- 区域淋巴结转移灶的[68Ga]Ga-DOTATATE中位SUVmax高于[18F]FDG(9.11 vs. 6.12,P<0.001),骨和内脏转移灶摄取相当。
- 大多数鼻咽癌病灶(85.7%)显示强烈SSTR2表达,与[68Ga]Ga-DOTATATE摄取强相关。
- SSTR2阴性病灶的SUVmax显著低于SSTR2阳性病灶(4.95 vs. 12.61,P=0.013)。
关键数值与推荐
- 原发灶SUVmax:12.03 vs. 10.07(P=0.048);肿瘤/脑比值:36.16 vs. 0.86(P<0.001)。
- 区域淋巴结转移灶中位SUVmax:9.11 vs. 6.12(P<0.001)。
- SSTR2阴性病灶SUVmax 4.95 vs. SSTR2阳性病灶12.61(P=0.013)。
- 85.7%的鼻咽癌病灶显示强烈SSTR2表达。
临床怎么用
- [68Ga]Ga-DOTATATE PET/CT可作为鼻咽癌原发灶和转移灶检测的显像选择,图像对比度好,诊断效能与[18F]FDG PET/CT相当。
- 可利用[68Ga]Ga-DOTATATE PET/CT无创评估鼻咽癌SSTR2表达状态,为生长抑素受体靶向诊疗提供依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To explore the feasibility of [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with non-keratinizing nasopharyngeal carcinoma (NPC) and to evaluate whether [68Ga]Ga-DOTATATE PET/CT could be used for non-invasive determination of somatostatin receptor 2 (SSTR2) expression in NPC. METHODS: This prospective study included patients with NPC who underwent [68Ga]Ga-DOTATATE PET/CT between February and May 2021. The [68Ga]Ga-DOTATATE and [18F]FDG uptakes in primary and metastatic NPC lesions were calculated and compared, and the [68Ga]Ga-DOTATATE uptake between SSTR2 score groups was analysed. RESULTS: A total of 36 participants (25 patients, initial staging; 11 patients, recurrence detection) were included; 33 patients also underwent [18F]FDG PET/CT for staging/restaging as a part of their routine diagnostic workup. [68Ga]Ga-DOTATATE PET/CT showed an intense tracer uptake in primary and metastatic NPC lesions. The radiotracer uptake was higher with [68Ga]Ga-DOTATATE than with [18F]FDG PET in primary NPC lesions (SUVmax: 12.03 vs. 10.07, P = 0.048; tumour-to-brain ratio: 36.16 vs. 0.86, P < 0.001) and regional lymph node metastases (median SUVmax: 9.11 vs. 6.12, P < 0.001) and comparable in bone and visceral metastases. Importantly, most NPC lesions showed intense SSTR2 expression (85.7%), which was strongly correlated with the [68Ga]Ga-DOTATATE uptake. The SUVmax of SSTR2-negative lesions was significantly lower than that of SSTR2-positive lesions (SUVmax: 4.95 vs. 12.61, P = 0.013). CONCLUSION: [68Ga]Ga-DOTATATE PET/CT is a promising imaging modality for detecting primary and metastatic NPC, with favourable image contrast and comparable diagnostic efficacy when compared to [18F]FDG PET/CT. An intense SSTR2 expression was observed in most NPCs, and this expression was significantly correlated with the [68Ga]Ga-DOTATATE uptake.
引用
- Zhao L, Pang Y, Wang Y, et al. Somatostatin receptor imaging with [68Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021. PMID: 34665275. doi:10.1007/s00259-021-05587-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。